The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata

Spies, James B.

doi:10.1016/s0029-7844(01)01702-1

Cited by 390 publications

(238 citation statements)

References 11 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…6 In addition to the physical symptoms, validated quality of life measures indicate that uterine leiomyomas impact women emotionally, including increased fears about their health along with additional considerations with regard to relationships, sexual function, body image, loss of control, and hopelessness. 7 Further, the economic impact of this disease is probably underestimated given the limited amount of information on its impact on women’s work. The purpose of this study is to provide a comprehensive assessment of the burden and impact of uterine leiomyomas in a diverse group of women.…”

Section: Introductionmentioning

confidence: 99%

The impact of uterine leiomyomas: a national survey of affected women

Borah

Nicholson²,

Bradley

et al. 2013

American Journal of Obstetrics and Gynecology

233

173

View full text Add to dashboard Cite

Objectives To characterize the impact of uterine leiomyomas (fibroids) in a racially diverse sample of women in the United States. Study Design A total of 968 women (573 White, 268 African-American, 127 other races) aged 29–59 with self-reported symptomatic uterine leiomyomas participated in a national survey. We assessed diagnosis, information seeking, attitudes about fertility, impact on work, and treatment preferences. Frequencies and percentages were summarized. Chi-square test was used to compare age groups. Results Women waited an average of 3.6 years before seeking treatment for leiomyomas, and 41% saw two or more healthcare providers for diagnosis. Almost a third of employed respondents (28%) reported missing work due to leiomyoma symptoms, and 24% felt that their symptoms prevented them from reaching their career potential. Women expressed desire for treatments that do not involve invasive surgery (79%), preserve the uterus (51%), and preserve fertility (43% of women under 40). Conclusions Uterine leiomyomas cause significant morbidity. When considering treatment, women are most concerned about surgical options, especially women under 40 who want to preserve fertility.

show abstract

Section: Introductionmentioning

confidence: 99%

The impact of uterine leiomyomas: a national survey of affected women

Borah

Nicholson²,

Bradley

et al. 2013

American Journal of Obstetrics and Gynecology

233

173

View full text Add to dashboard Cite

show abstract

“…Preference was given to general QoL scales, such as the SF-36 [23] and HRQoL-4 [24], followed by condition-specific scales, such as the UFS-QoL [25]. …”

Section: Methodsmentioning

confidence: 99%

Combined Oral Contraceptive for Treatment of Women with Uterine Fibroids and Abnormal Uterine Bleeding: A Systematic Review

Moroni

Martins

Dias

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: We aimed at assessing the efficacy of combined oral contraceptives (COC) in treating women with uterine leiomyomata and heavy menstrual bleeding (HMB), as well as their effect over quality of life (QoL), tumor size, and hemoglobin concentration. Methods: We searched various electronic databases and reference lists from all included studies. Randomized and nonrandomized controlled clinical trials were selected, and two trials were considered eligible - one randomized and one ‘pseudo'-randomized. Results: COCs performed less well than levonorgestrel-releasing intrauterine systems (LNG-IUSs) in controlling HMB, improving QoL, and improving the hemoglobin concentration, whereas the estimate was not sufficiently precise to define whether COCs were better than, equal to, or worse than LNG-IUSs in reducing tumor size. It must be stressed that these results are based on low-quality evidence, stemming from a single trial. Additionally, COCs were more effective than placebo in tumor size reduction, another conclusion based on another single study, considered as being at a high risk of bias and judged as very low-quality evidence. Conclusion: Evidence regarding the use of COCs as treatment for women with symptomatic fibroids is very scarce and of low quality, and we are very uncertain about the real efficacy of such treatment.

show abstract

“…Eligible premenopausal women were asked to complete a validated Symptom Severity Score (SSS) from the uterine fibroid symptom and quality of life (UFS-QOL) questionnaire [22]. The scores were transformed to create a transformed SSS, yielding a 0 to 100 point scale with higher scores indicating worse symptoms [22]. Patients with SSS ≥ 41 (i.e., symptomatic uterine fibroids) were scheduled for a medical and gynecological assessment.…”

Section: Methodsmentioning

confidence: 99%

MR-guided focused ultrasound (MRgFUS) is effective for the distinct pattern of uterine fibroids seen in African-American women: data from phase III/IV, non-randomized, multicenter clinical trials

et al. 2013

View full text Add to dashboard Cite

BackgroundUterine fibroids are common among women at the reproductive age. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is a novel and a conservative treatment for symptomatic cases. The aim of the study was to evaluate the efficacy of MRgFUS in African-American (AA) women compared with that in non-African-Americans (non-AA).MethodsA single-armed phase IV study was conducted to establish the efficacy of treatment in AA women. Comparison of patient, fibroid, and treatment characteristics from this trial was compared with that of the previously published phase III trial. Both studies were approved by the IRB of each medical center.ResultsSixty-three AA and 59 non-AA women were treated with MRgFUS. Although AA women had a different pattern of disease, outcomes were similar in both groups. AA patients had a significant higher total number of fibroids compared with non-AA (median 6.0, interquartile range (IQR) 3.0–10.0 vs. 2.0, IQR 1.0–4.0, respectively, p < 0.001), although their total fibroid volume was significantly smaller (median 196.9 cm3, IQR 112.8–415.3 cm3 vs. 394.8 cm3, IQR 189.8–674.4 cm3, respectively, p < 0.001). AA women were younger compared with non-AA (mean ± SD 43.4 ± 5.1 vs. 46.3 ± 4.1 years of age, respectively, p = 0.001) when they presented for treatment. The rate of alternative treatments as well as fibroid-associated symptoms at follow-up time points (3, 6, 12, 24, and 36 months, period following MRgFUS treatment) did not differ according to race (p ≥ 0.62).ConclusionDespite differences in the pattern of fibroid disease, MRgFUS for uterine fibroids has a similar efficacy for AA women compared with non-AA women.

show abstract

The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata

Abstract: The UFS-QOL appears to be a useful new tool for detecting differences in symptom severity and health-related quality of life among patients with uterine leiomyomata. Additional study is underway to determine the responsiveness of the UFS-QOL to therapies for leiomyomata.

Cited by 390 publications

References 11 publications

The impact of uterine leiomyomas: a national survey of affected women

The impact of uterine leiomyomas: a national survey of affected women

Combined Oral Contraceptive for Treatment of Women with Uterine Fibroids and Abnormal Uterine Bleeding: A Systematic Review

MR-guided focused ultrasound (MRgFUS) is effective for the distinct pattern of uterine fibroids seen in African-American women: data from phase III/IV, non-randomized, multicenter clinical trials

Contact Info

Product

Resources

About